These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind? Bellmunt J; Nadal R Med; 2024 Jun; 5(6):490-492. PubMed ID: 38878766 [TBL] [Abstract][Full Text] [Related]
3. The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma? Benjamin DJ; Rezazadeh Kalebasty A; Prasad V Eur Urol Oncol; 2024 Jun; 7(3):313-315. PubMed ID: 38485615 [TBL] [Abstract][Full Text] [Related]
4. Enfortumab Vedotin and Pembrolizumab - A New Perspective on Urothelial Cancer. Niegisch G N Engl J Med; 2024 Mar; 390(10):944-946. PubMed ID: 38446680 [No Abstract] [Full Text] [Related]
5. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. Powles T; Valderrama BP; Gupta S; Bedke J; Kikuchi E; Hoffman-Censits J; Iyer G; Vulsteke C; Park SH; Shin SJ; Castellano D; Fornarini G; Li JR; Gümüş M; Mar N; Loriot Y; Fléchon A; Duran I; Drakaki A; Narayanan S; Yu X; Gorla S; Homet Moreno B; van der Heijden MS; N Engl J Med; 2024 Mar; 390(10):875-888. PubMed ID: 38446675 [TBL] [Abstract][Full Text] [Related]
6. Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data. Uemura K; Ito H; Jikuya R; Kondo T; Tatenuma T; Kawahara T; Ito Y; Komeya M; Muraoka K; Hasumi H; Uemura H; Makiyama K Int J Urol; 2024 Jun; 31(6):678-684. PubMed ID: 38402449 [TBL] [Abstract][Full Text] [Related]
7. Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer. Zhu X; Koshkin VS Med; 2024 Feb; 5(2):106-108. PubMed ID: 38128535 [TBL] [Abstract][Full Text] [Related]
8. Is there a role for pembrolizumab beyond progression in urothelial carcinoma? Taguchi S; Kawai T; Nakagawa T; Kume H BJU Int; 2024 Jul; 134(1):43-44. PubMed ID: 38073020 [No Abstract] [Full Text] [Related]
9. FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma. Maguire WF; Lee D; Weinstock C; Gao X; Bulik CC; Agrawal S; Chang E; Hamed SS; Bloomquist EW; Tang S; Pazdur R; Kluetz PG; Amiri-Kordestani L; Suzman DL Clin Cancer Res; 2024 May; 30(10):2011-2016. PubMed ID: 38441576 [TBL] [Abstract][Full Text] [Related]
10. A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab. Hoimes CJ; Flaig TW; Milowsky MI; Friedlander TW; Bilen MA; Gupta S; Srinivas S; Merchan JR; McKay RR; Petrylak DP; Sasse C; Moreno BH; Yu Y; Carret AS; Rosenberg JE Future Oncol; 2024 Mar; 20(7):351-360. PubMed ID: 37994649 [TBL] [Abstract][Full Text] [Related]
11. Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era. Kita Y; Ito K; Sano T; Hashimoto K; Mochizuki T; Shiraishi Y; Araki H; Fujiwara M; Kanamaru S; Takahashi T; Hishiki K; Okada T; Ogawa K; Ito M; Kojima T; Nishiyama N; Matsui Y; Nishiyama H; Kitamura H; Kobayashi T Int J Urol; 2022 Jul; 29(7):647-655. PubMed ID: 35304776 [TBL] [Abstract][Full Text] [Related]
12. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma. Powles T; Bellmunt J; Comperat E; De Santis M; Huddart R; Loriot Y; Necchi A; Valderrama BP; Ravaud A; Shariat SF; Szabados B; van der Heijden MS; Gillessen S; Ann Oncol; 2024 Jun; 35(6):485-490. PubMed ID: 38490358 [No Abstract] [Full Text] [Related]
13. Enfortumab Vedotin in Advanced Urothelial Carcinoma. Yeon SH; Lee HJ N Engl J Med; 2021 Jul; 385(1):93. PubMed ID: 34192440 [No Abstract] [Full Text] [Related]
14. Enfortumab Vedotin in Advanced Urothelial Carcinoma. Reply. Petrylak DP; Powles T; Rosenberg JE N Engl J Med; 2021 Jul; 385(1):93-94. PubMed ID: 34192441 [No Abstract] [Full Text] [Related]
15. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. Powles T; Rosenberg JE; Sonpavde GP; Loriot Y; Durán I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Wu C; Campbell M; Matsangou M; Petrylak DP N Engl J Med; 2021 Mar; 384(12):1125-1135. PubMed ID: 33577729 [TBL] [Abstract][Full Text] [Related]